- Home
- DRUG vs LXEO Comparison
DRUG vs LXEO Comparison
Compare DRUG & LXEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DRUG
- LXEO
- Stock Information
- Founded
- DRUG 2019
- LXEO 2017
- Country
- DRUG United States
- LXEO United States
- Employees
- DRUG N/A
- LXEO N/A
- Industry
- DRUG Pharmaceuticals and Biotechnology
- LXEO
- Sector
- DRUG Health Care
- LXEO
- Exchange
- DRUG Nasdaq
- LXEO Nasdaq
- Market Cap
- DRUG 345.6M
- LXEO 290.5M
- IPO Year
- DRUG N/A
- LXEO 2023
- Fundamental
- Price
- DRUG $55.20
- LXEO $8.03
- Analyst Decision
- DRUG Strong Buy
- LXEO Strong Buy
- Analyst Count
- DRUG 9
- LXEO 7
- Target Price
- DRUG $81.67
- LXEO $16.71
- AVG Volume (30 Days)
- DRUG 90.8K
- LXEO 1.3M
- Earning Date
- DRUG 08-11-2025
- LXEO 11-12-2025
- Dividend Yield
- DRUG N/A
- LXEO N/A
- EPS Growth
- DRUG N/A
- LXEO N/A
- EPS
- DRUG N/A
- LXEO N/A
- Revenue
- DRUG N/A
- LXEO N/A
- Revenue This Year
- DRUG N/A
- LXEO N/A
- Revenue Next Year
- DRUG N/A
- LXEO N/A
- P/E Ratio
- DRUG N/A
- LXEO N/A
- Revenue Growth
- DRUG N/A
- LXEO N/A
- 52 Week Low
- DRUG $0.94
- LXEO $1.45
- 52 Week High
- DRUG $79.02
- LXEO $11.72
- Technical
- Relative Strength Index (RSI)
- DRUG N/A
- LXEO 82.85
- Support Level
- DRUG N/A
- LXEO $6.33
- Resistance Level
- DRUG N/A
- LXEO $8.88
- Average True Range (ATR)
- DRUG 0.00
- LXEO 0.56
- MACD
- DRUG 0.00
- LXEO 0.19
- Stochastic Oscillator
- DRUG 0.00
- LXEO 86.77
About DRUG Bright Minds Biosciences Inc.
Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.
About LXEO Lexeo Therapeutics Inc.
Lexeo Therapeutics Inc is a clinical-stage genetic medicines company committed to transforming healthcare by applying pioneering science to fundamentally alter how diseases are treated. The company focuses on preclinical and clinical stage gene therapies, specifically hereditary and acquired diseases with high unmet needs, which represent its sole business segment.